1.
|
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 0903X-100847, NCT00161668
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 to 60
Sponsor: NCI, Other
Protocol IDs: CDR0000258113, ECOG-1900, E1900, NCT00049517
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 61 to 75
Sponsor: Other
Protocol IDs: EORTC-06012, AML-17, GIMEMA-AML-17, NCT00052299
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: CDR0000360812, U10CA032102, S0106, SWOG-S0106, NCT00085709
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 61 and over
Sponsor: Other
Protocol IDs: SAKK-AML-43, EU-20514, HOVON-AML-43, NCT00121303
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: AML02, 5R01CA113482, NCT00136084
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 30
Sponsor: NCI
Protocol IDs: COG-AAML0531, AAML0531, NCT00372593
|
|
8.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0521, S0521, NCT00492856
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and under
Sponsor: Other
Protocol IDs: NOPHO-AML 2004, NCT00476541
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 50 to 70
Sponsor: Other
Protocol IDs: ALFA 0701, NCT00927498
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 55 to 75
Sponsor: Other
Protocol IDs: ID01-010, NCT00038831
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KAN-979-02, NCT00233909
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: W-AR-0903B1-201-US, CDR0000065896, UCCRC-8600, NCI-V97-1355, NCT00003131
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: W-AR-0903B1-203-US, CDR0000066771, NCI-V98-1497, NCT00003673
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-4999, NCT00005962, E4999
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 61 and over
Sponsor: Other
Protocol IDs: EORTC-06993, EORTC-06993-AML-15, NCT00006122
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 17 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068208, U10CA031946, CALGB-19902, NCT00006265
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENTA-GA210, UCCRC-10928, NCT00017589
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0012052, W-AR-0903B1-207-US, NCI-G01-1996, NCT00022321
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 1 month to 21 years
Sponsor: NCI
Protocol IDs: COG-AAML03P1, NCT00070174, AAML03P1
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 to 70
Sponsor: Other
Protocol IDs: EORTC-06013, NCT00077116
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 59
Sponsor: Other
Protocol IDs: 0903B1-206, NCT00037583
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 0903B1-205, NCT00037596
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CCF6818, P30CA043703, CASE-CCF-6818, NCT00274781
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Other
Protocol IDs: AMLSG05-04, NCT00143975
|
Mobile | Español
